NOVOTECH INITIATES PHASE IB CANCER TRIALS IN AUSTRALIA AND NEW ZEALAND FOR CLIENT, ONCOMED PHARMACEUTICALS Sydney, Australia, 29 October 2010 – Novotech has announced initiation of three Phase Ib oncology trials at sites in Australia and New Zealand to test the safety, efficacy and pharmacokinetics of client OncoMed’s humanized monoclonal antibody... Read more
October 29th, 2010
Novotech initiates cancer trials in Australia and New Zealand for Oncomed Pharmaceuticals
October 27th, 2010
Novotech Selects Oracle’s Siebel Clinical Trial Management System to Support Continued Growth
Novotech Selects Oracle’s Siebel Clinical Trial Management System to Support Continued Growth Sydney, Australia – 27 October, 2010 News Facts Novotech, the largest independent clinical research organisation in Australia, has selected Oracle’s Siebel Clinical Trial Management System to support the company’s complete spectrum of clinical drug... Read more
June 15th, 2010
Novotech CEO to speak on Clinical Projects – Faster and Smarter it’s All in the Planning at the 46th DIA Annual Meeting June 13-17 in Washington, DC
Washington, DC, June 13, 2010 – Leading Australian contract clinical research company Novotech announced today that Novotech CEO Alek Safarian will be sharing the company’s Asia Region expertise and experience at DIA 2010 to be held in Washington, DC. Safarian will speak on “Global Study Experiences: Lessons from Observing Regional Variations”... Read more
April 15th, 2010
Novotech embarks on a new strategic partnership with Citeline, designed to accelerate patient recruitment and complete clinical studies more quickly.
Novotech embarks on a new strategic partnership with Citeline, designed to accelerate patient recruitment and complete clinical studies more quickly. NEW YORK – 15/4/10 – Novotech, a leading Australasian CRO, has engaged Citeline to support its clinical development programs and further improve the rate at which Sponsor clinical studies are planned... Read more
October 27th, 2009
Novotech announces four country Asia expansion at AusBiotech 2009
NOVOTECH ANNOUNCES FOUR COUNTRY ASIA EXPANSION AT AUSBIOTECH 2009 New operations in Malaysia, Singapore, Thailand, and Philippines Sydney, Oct 27, 2009 – Leading Australian contract clinical research company Novotech announced today that it was expanding into four new Asian markets with the establishment of a management hub in Kuala Lumpur, Malaysia. Novotech... Read more
August 31st, 2009
New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in Australia
New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in Australia Sydney, Australia – 31, August 2009 – It was announced today that a new global clinical trial has begun enrolling patients with Alzheimer’s disease in NSW, Victoria, Queensland, South Australia, and Western Australia. The CONCERT study, is... Read more
June 19th, 2008
Novotech wins coveted Australian CRO Award from Frost & Sullivan
San Diego, CA– June 19, 2008 — Novotech, the largest Australian owned contract research organization (CRO) has confirmed its position as the pre-eminent Australian based CRO with the award by leading industry analyst house Frost & Sullivan as the Australian CRO of the Year. The award is part of the prestigious Excellence in Healthcare Awards... Read more
November 17th, 2007
Athletes, and non-athletes, between 18 and 65 wanted for tinea study
ATHLETES’ FOOT AFFECTS MORE THAN 9% OF PEOPLE Sydney, Australia – November 17, 2007 – A novel new oral treatment for Tinea, commonly known as Athletes’ Foot, is now being tested by Australian research teams in Melbourne, Sydney, Adelaide and Brisbane as part of a global study in the condition that affects over 9% of Australians. According... Read more
November 14th, 2007
Australian research teams test prawn shell treatment to combat hayfever
“DRUG FROM THE SEA” SHOWS POTENTIAL FOR ALLERGY SUFFERERS Sydney, Australia – November 14, 2007 – A novel agent for the treatment of rhinitis, commonly known as hayfever, is now being tested by Australian research teams in Melbourne, Sydney, and Brisbane. The agent is derived from the shells of marine crustaceans. Dr Rimmer from the... Read more
October 21st, 2007
Novotech in expansion mode as CRO sector continues to grow at 15%
BioPacificVentures and Co-Investor Capital Partners invest in Novotech and back expansion plans Sydney, Australia, Orange County, CA – October 21, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, is now in rapid expansion mode as the CRO sector fundamentals continue to... Read more
July 1st, 2007
Novotech alerts Pharma and Biotechs at DIA 2007 to Australias new R&D tax break that applies to clinical trials
New Tax break comes into effect July 1, 2007 Atlanta, GA – July 1, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, announced on the eve of DIA 2007 that the new tax breaks for research in Australia, which includes clinical trials, starts July 1, 2007. Novotech CEO Alek... Read more
May 15th, 2007
Novotech says Australia ideally placed to become Bioequivalence trials hub
Sydney, Australia, May 15, 2007 — Novotech, the largest independent Australian owned contract research organization (CRO) with expertise in TGA/EMEA/FDA registration said today Australia should aggressively market its bioequivalence trials capabilities overseas and take a large share of the multi-billion dollar sector. Already more than 70% of Novotech’s... Read more
May 8th, 2007
Updated checklist for CRO partnering and trials selection in Australasian region announced at BIO 2007
May 8, 2007 – Boston, MA — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, has released its updated “Clinical Trials Checklist” for CROs, biotech, pharma and even VCs, to assist in the often challenging task of selecting a clinical trials partner in the Australasian... Read more
December 12th, 2006
Novotech recognized in Deloitte Technology Fast 500 Asia Pacific 2006 Program
Dec 12, 2006 – Sydney, Australia Novotech, the largest independent Australian owned contract research organization (CRO) and the only Australian CRO with offices in the USA, announced today that it is a winner in the Deloitte Fast 500 Asia Pacific 2006 Program. The Program run by the leading global consultancy, is supported by the Deloitte Technology... Read more
October 3rd, 2006
Novotech CRO opens second office in the USA
Oct 3, 2006 – Sydney, Australia — Novotech, the largest independent Australian owned contract research organization (CRO) announced today it has accelerated its US expansion plans with the opening of a second office in the USA specifically designed to service the maturing Australian biotech sector. Novotech CEO Alek Safarian said the new office... Read more
June 21st, 2006
Novotech presents checklist for CRO partnering and trials selection in Australia & Asia at DIA 2006
June 21, 2006 – Philadelphia, PA — Novotech, the largest Australian owned contract research organization (CRO) presented to the Drug Industry Association (DIA) annual conference 2006 this week, a check list for the selection of a CRO in Australia and the Asian region. At Novotech’s DIA press conference, Novotech CEO Alek Safarian said all... Read more
June 21st, 2006
Novotech checklist for CRO partnering and trials selection is Australia & Asia
June 21, 2006 – Philadelphia, PA —Size match – ensure the CRO is a good match in organizational size and reach. Make sure the CRO has experience working with companies at a similar stage and growth phase, eg, small to medium sized biotechs often find it frustrating working with the large global CROs as they can struggle with response times... Read more
June 20th, 2006
Novotech wins prestigious Asian CRO of The Year Award
June 20, 2006 – Philadelphia, PA — Novotech, the largest Australian owned contract research organization (CRO) announced today it has been recognized by Frost & Sullivan for its clinical research capabilities at the inaugural Asia Pacific Healthcare Best Practice Awards, winning The Asian CRO of the Year – Australia Award. According... Read more
April 9th, 2006
Novotech’s expansion to USA reaps multimillion
April 9, 2006 – Chigago, Il — Novotech, the largest Australian owned contract research organization (CRO) announced today at BIO 2006 in Chicago Il., an AUD4 million deal with US biotech firm SkyePharma (LSE: SKP; Nasdaq: SKYE) to conduct a key trial required for the US FDA. This is the first major deal for Novotech’s new US operations which... Read more
November 2nd, 2005
Novotech Receives “Highly Commended” in NSW Premier’s 2005
Nov 2, 2005 – Sydney, Australia — Novotech, Australia’s leading contract research organization (CRO), today announced that it has been awarded an “Highly Commended’ accolade in the prestigious NWS Premier’s 2005 Exporter of the Year Awards. Novotech CEO Alek Safarian, who attended the award’s ceremony, said he was very pleased to represent... Read more
September 9th, 2005
Novotech CEO invited to chair clinical trials
Sept 9, 2005 – London, UK — Novotech, the largest Australian full-service contract research organization (CRO) – with offices also in the UK and USA- , has accepted the London based Pharmaceutical & Biotech Outsourcing Research & Development Expo & Conference’s [PABORD] invitation for Novotech CEO Alek Safarian to chair the... Read more
June 22nd, 2005
Novotech launches innovative clinical trials risk
June 22, 2005 – Philadelphia, PA — Novotech, Australia’s largest contract research organization (CRO), today announced the launch of its Risk Sharing offering which guarantees massive savings on clinical trial costs for US firms in return for drug license rights in Australia and New Zealand. Novotech, which was this year awarded the prestigious... Read more
April 4th, 2005
Novotech, Quintiles and Pharma firms debate pros and cons
April 4, 2005 – Dallas, Texas — Novotech, Australia’s leading contract research organization (CRO), today announced that Novotech CEO Alek Safarian will debate the pros and cons of outsourcing globally at the 14th Annual Partnership with CROs and other Outsourcing Providers (April 4-6 Dallas). Other panelists include executives from pharma... Read more
March 17th, 2005
IDC/LSI Report identifies Australia as a key region
March 17, 2005 – Sydney, Australia — Novotech, Australia’s leading contract research organization (CRO), said premier market intelligence firm Life Science Insights (LSI), part of the IDC group, had identified Australia as a prime site for CRO outsourcing following a briefing with Novotech in California recently. Alek Safarian, Novotech CEO,... Read more
March 14th, 2005
Novotech to present benefits of outsourcing clinical
March 14, 2005 – Boston, MA — Novotech, Australia’s leading contract research organization (CRO), CEO Alek Safarian has been invited to present Australia’s outstanding clinical trials capabilities at the inaugural Sachs Bloomberg CRO Partnering Forum in Boston (March 15, 2005). In the past three years, Novotech has worked with more than... Read more
December 7th, 2004
Novotech appoints DatelineMedia (USA) as Communications
Dec 7, 2004 – San Francisco, CA – Novotech, Australia’s leading clinical research organization (CRO), has appointed DatelineMedia Communications (USA) as its agency of record for PR and media strategy in the U.S. Alek Safarian, Novotech CEO, said editorial media coverage played a significant role in the company’s business development program... Read more
October 14th, 2004
U.S. Biotech and Pharma Industry leaders gather
Oct 14, 2004 – Washington DC — Novotech, Australia’s leading contract research organization (CRO), and the Australian Embassy are hosting a clinical trials and biopartnering networking event next week to showcase the considerable business opportunities for U.S. biotech and pharma in Australia. Date: October 25, 2004 Time: 6.30pm – 8.30pm... Read more
June 6th, 2004
Australian-based CRO Novotech unveils plans to open in the U.S
June 6, 2004 – San Francisco, CA — Riding on a wave of successful bids for U.S clinical trials contracts, Novotech CEO Alek Safarian will outline plans to open operations in the U.S. at this week’s BIO 2004, San Francisco (www.bio.org ). During the conference Safarian will host functions with biotech executives and VCs to discuss Novotech’s... Read more
April 26th, 2004
Novotech eases drug development bottleneck
April 26, 2004 – Orlando, Florida — Clinical research trials in Australia can begin in as little as 2-3 months from the initiation of the approval process and cost up to 30% less than comparable Western countries such as the US and Europe. Alek Safarian, CEO of Australia’s largest CRO Novotech said Australian regulatory procedures were supportive... Read more
March 31st, 2004
FDA approves Tarceva for patients with advanced…
March 31, 2004 – Sydney, Australia — Novotech, Australia’s leading contract research organization (CRO), today announced that it was involved in the highly successful trial for Tarceva ™ (erlotinib) which was recently approved by the U.S. Food and Drug Administration (FDA), after priority review. Tarceva ™, produced by OSI Pharmaceuticals,... Read more
